Lead CMC drug substance phase-appropriate development activities to ensure Module 3 content that supports global clinical filings and registration plans
Serve as the technical SME and process owner for drug substance; develop scalable and robust manufacturing processes for oligonucleotides and peptide products with CDMOs
Author IND and NDA Module 3 content, Master Batch Records, Validation Plans and Reports
Ensure robust regulatory plans for changes while minimizing risk to product supply
Foster effective teamwork and drive project execution; track critical path activities, anticipate risks, create contingency plans, update timelines and budgets, and maintain the CMC program plan
Regularly interact with Regulatory, Quality, Supply Chain, Commercial, Medical, Clinical, and non-Clinical development
Manage external resources including consultants and contractors as needed
Travel to global manufacturing sites to support operations and validation activities
Requirements
Bachelor’s degree in organic chemistry, chemical engineering, or related field (MS or PhD preferred)
A solid understanding of small molecule, RNA, and amino acid chemistries
At least 15 years of experience in API development from early through late-phase
Prior process validation experience preferred
Experience developing oligonucleotide and/or synthetic peptide processes including impurity control strategies
Experience leading global, cross-functional, high performing teams
Prior experience leading or serving on a CMC team preferred
Advanced knowledge of cGMP/GLP regulations, ICH, FDA CMC Guidance Documents
A strong track record of successful global CMC submissions and approvals
Ability to function independently and influence stakeholders and recommend scientifically rigorous, phase appropriate, risk-management based solutions
Experience working with contract manufacturing organizations